Anzeige
Mehr »
Login
Donnerstag, 03.12.2020 Börsentäglich über 12.000 News von 648 internationalen Medien
Goldman Sachs sieht Kupfer bei 10.000 USD! Jetzt profitieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV ISIN: IE00B91XRN20 Ticker-Symbol: 0PT 
Tradegate
02.12.20
16:00 Uhr
9,150 Euro
+0,050
+0,55 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
8,9509,30002.12.
9,1009,15002.12.

Aktuelle News zur PROTHENA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PROTHENA Aktie jetzt für 0€ handeln
18.11.Prothena (PRTA) Investor Presentation - Slideshow1
09.11.Prothena Corporation plc 2020 Q3 - Results - Earnings Call Presentation-
05.11.Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates2
04.11.PROTHENA CORP PUBLIC LTD CO - 10-Q, Quaterly Report1
04.11.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report1
04.11.Prothena Corporation plc: Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update828Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020; quarter-end cash and restricted cash position of...
► Artikel lesen
04.11.Prothena Corporation plc: Prothena Announces Presentations on Two Programs from its Alzheimer's Disease Portfolio at CTAD 2020274Next generation anti-Aß antibodies being developed for subcutaneous administration to improve access for patients with Alzheimer's diseaseMulti-immunogen Aß-tau vaccine being developed for...
► Artikel lesen
28.10.Prothena Corporation plc: Prothena to Report Third Quarter 2020 Financial Results on November 4895DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...
► Artikel lesen
21.10.Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II2
21.10.The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings7
21.10.Roche and Prothena set to advance Parkinson's disease candidate into phase 2b3
21.10.Unfazed by PhII miss, Roche ushers Prothena's Parkinson's drug into late-stage trial - a $60M move11
21.10.Roche, Prothena To Advance Prasinezumab Into Phase 2b Study In Parkinson's Disease1.780SOUTH SAN FRANCISCO (dpa-AFX) - Prothena Corporation plc (PRTA) announced plans to advance prasinezumab into a Phase 2b study, along with Roche (RHHBY), in patients with early Parkinson's...
► Artikel lesen
20.10.Prothena Corporation plc: Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson's Disease1.808First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson's disease; expected to initiate in 2021Prothena to earn a $60 million clinical...
► Artikel lesen
20.10.PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report3
02.10.Prothena Corporation plc: Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)307DUBLIN, Ireland, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
► Artikel lesen
15.09.Prothena Corporation plc: Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress799DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
► Artikel lesen
11.09.Prothena Corporation plc: Prasinezumab Slows Progression on Measures of Parkinson's Disease in Phase 2 Study940First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor...
► Artikel lesen
08.09.Prothena Corporation plc: Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15918DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
► Artikel lesen
03.09.Prothena Corporation plc: Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson's Disease and Movement Disorders976DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational...
► Artikel lesen
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1